Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 May 19;9(5):e98315. doi: 10.1371/journal.pone.0098315

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 Rossi et al

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.

PMC Copyright notice

PBMCs were incubated overnight with 10 µg/mL of various mAbs or bsHexAbs prior to measurement of surface antigens by flow cytometry. (A) Gating of lymphocytes by forward vs. side scattering (Left) and B cells from the lymphocyte gate using CD19 and CD22 staining (Right) following treatment with control mAb (labetuzumab). (B) Example dot-plots comparing CD19 and CD22 staining on B cells following treatment of PBMCs with 22*-(20)-(20), epratuzumab and labetuzumab (Left) and histograms showing β7 integrin staining following treatment with the indicated mAbs or bsHexAbs (Right). (C) Trogocytosis mediated by C_k and C_H3-based bsAbs. PBMCs were incubated overnight with 10 µg/mL 22*-(20)-(20), 22-(20)-(20), veltuzumab, epratuzumab or labetuzumab (control), prior to measurement of surface CD19, CD22 and CD21 by flow cytometry. Results are shown as the % MFI of the control treatment. Error bars, Std. Dev.